Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
This PKI news page is best understood in the context of the information provided for Revvity, Inc. (NYSE: RVTY), which appears in the supplied news releases. While PKI historically referred to PerkinElmer in analytical laboratory instrument manufacturing, the current news flow in the input is associated with Revvity, a health science company whose activities span discovery to development, and diagnosis to cure.
The news items describe Revvity as providing health science solutions, technologies, expertise, and services, with focus areas that include translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. They also note that Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia, and governments, and that it is part of the S&P 500 index with customers in more than 160 countries.
Across the sample releases, typical news topics include quarterly financial results, dividend declarations, product launches in diagnostics and life sciences, and participation in healthcare investor conferences. Examples in the input include announcements of new reagent technologies for drug discovery, reference standards for oncology diagnostic testing workflows, and automated analytical platforms for specialty testing, as well as updates on earnings calls and financial performance.
For users researching PKI, this page therefore functions as an entry point into the more recent narrative presented under Revvity’s RVTY symbol in the provided material. Readers can use the news feed to follow themes such as health science product introductions, diagnostics and life sciences workflow tools, and financial reporting, as reflected in the supplied press releases.
Revvity (NYSE: RVTY) has announced its upcoming fourth quarter and full year 2024 financial results release, scheduled for January 31, 2025, before market open. The company will host a conference call at 8:00 a.m. ET on the same day.
In preliminary Q4 2024 results, Revvity expects reported revenue growth of 5% and organic revenue growth of 6% compared to the previous year, projecting quarterly revenue of approximately $730 million. The company anticipates meeting or exceeding its full year 2024 adjusted earnings per share guidance previously provided on November 4, 2024.
Additionally, CEO Prahlad Singh will present at the 43rd annual J.P. Morgan Healthcare Conference on January 13, 2025, at 8:15 a.m. PT.
Revvity (NYSE: RVTY) has received FDA 510(k) clearance for EUROIMMUN's automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This marks a significant milestone as the first FDA-cleared test for direct quantitative measurement of free testosterone levels in human serum or plasma.
The innovative assay, which runs on the company's iSYSTM or i10TM instruments, delivers results in just 48 minutes with a throughput of nearly 60 tests per hour. The test features monoclonal antibodies for consistent performance and specificity across batches.
This advancement enhances diagnostic capabilities for conditions including hypogonadism, impotence, polycystic ovarian syndrome (PCOS), and other androgenital syndromes, offering a user-friendly, random-access platform solution for direct free testosterone measurement.
Revvity (NYSE: RVTY) has announced its participation in the 43rd annual J.P. Morgan Healthcare Conference scheduled for January 13, 2025, at 8:15 a.m. PT in San Francisco. President and CEO Prahlad Singh will present an update on the company's strategic priorities and overall direction. The presentation will be accessible through a live audio webcast, with a replay available on the Revvity Investor Relations website for a minimum of 30 days following the event.
Revvity (NYSE: RVTY) announced an expanded collaboration with Genomics England to advance genomic initiatives across the UK. The partnership focuses on the Generation Study, a research program aiming to screen up to 100,000 newborns for 200 rare genetic conditions in England. Through its Omics laboratory in Manchester, Revvity will extract DNA from cord blood samples using the chemagic 360™ instrument. The collaboration aims to advance early detection of genetic conditions in newborns while also supporting the development of genomics talent across the UK region.
Revvity (NYSE: RVTY) has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference scheduled for December 3, 2024, at 8:20 a.m. ET in Coral Gables, FL. President and CEO Prahlad Singh will present an update on the company and its strategic priorities. The presentation will be accessible through a live audio webcast on the company's website's Events section, with a replay available on the Revvity Investor Relations website for at least 30 days following the event.
Scale Biosciences and Revvity's BioLegend (NYSE: RVTY) have launched the TotalSeq Phenocyte solution, a groundbreaking single-cell protein profiling technology. This innovation combines Scale Bio's Quantum Barcoding technology with BioLegend's TotalSeq antibody conjugates to enable more efficient identification and characterization of rare cell subtypes in immunology and oncology research.
The solution offers advantages over traditional methods like mass cytometry and flow cytometry by eliminating complex panel optimization and sophisticated instrumentation requirements, making it more accessible and scalable. It builds upon BioLegend's TotalSeq-A antibody panels and supports biomarker discovery without requiring dedicated instrumentation.
Revvity (NYSE: RVTY) has announced its upcoming Investor Day scheduled for November 21, 2024, at 9:00 a.m. PT. The company revealed strategic changes to its operating model, effective fiscal year 2025, including the integration of its Applied Genomics business into a new Life Sciences Solutions division.
The reorganization will result in two main reporting segments: Life Sciences (comprising Life Sciences Solutions and Software) and Diagnostics (including Immunodiagnostics and Reproductive Health). This restructuring aims to enhance operational efficiency, create synergies, and improve customer service delivery.
Revvity reported strong Q3 2024 financial results with revenue reaching $684 million, representing 2% reported and organic growth. GAAP EPS was $0.77, while adjusted EPS from continuing operations reached $1.28. The company's Diagnostics segment showed 6% growth with $383 million revenue, while Life Sciences recorded $301 million, a 2% decrease. Operating margins improved, with GAAP operating profit margin at 14.3% and adjusted operating profit margin at 28.3%. The company raised its full-year 2024 adjusted EPS guidance to $4.83-$4.87 and announced a new $1 billion share repurchase program.
Revvity (NYSE: RVTY) announced that its Board of Directors has declared a quarterly dividend of $0.07 per share of common stock. The dividend will be paid on February 7, 2025, to shareholders of record as of the close of business on January 17, 2025.
Revvity, Inc. (NYSE: RVTY) has launched Revvity Transcribe AI, an innovative optical character recognition (OCR) service that converts handwritten text on test request forms into digital format. This solution aims to streamline workflows and reduce manual data entry tasks in clinical laboratories. Key features include:
- 40% improvement in overall data entry workflow speed, including data validation
- Especially valuable for newborn screening (NBS) laboratories
- Compatible with Revvity's EVOYA™ platform for NBS software
- Secure data processing with ISO27001 compliance
The service allows laboratory personnel to focus on other essential tasks by automating the manually intensive process of transcribing handwritten information. Revvity Transcribe AI will be introduced at the 2024 APHL Newborn Screening Symposium in Omaha, Nebraska.
FAQ
What is the market cap of PERKINELMER (PKI)?
